Justin Klein is a Partner on NEA’s healthcare team.  He joined NEA in 2006 and focuses on medical device, healthcare technology, specialty pharma and biopharmaceutical company investments.  He is actively involved with NEA’s investments as a director of Legato Medical, PhaseBio Pharmaceuticals, Relievant Medsystems, Topera Medical, Ulthera, VertiFlex, and VytronUS, and as a board observer for Carticept Medical, Cartiva, ExploraMed, Moximed, Neuropace, Senseonics, and TriVascular.  Justin’s past board memberships include CV Ingenuity (acquired by Covidien in 2013).  Justin is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC).

Previously, Justin worked for the Duke University Health System, reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations. In addition, he has worked at Latham & Watkins LLP in Menlo Park, where he assisted life sciences companies on numerous licensing transactions, regulatory and corporate securities matters. Justin has served as a member of the Board of Trustees of Duke University, and previously served on the medical center’s Institutional Review Board. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He received his AB in Economics and his BS in Biological Anthropology and Anatomy from Duke University.